Victory Capital Management Inc. Buys 12,643 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Victory Capital Management Inc. lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 174.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,899 shares of the company's stock after purchasing an additional 12,643 shares during the quarter. Victory Capital Management Inc.'s holdings in Kymera Therapeutics were worth $801,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. lifted its position in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. KBC Group NV boosted its stake in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after acquiring an additional 752 shares during the period. Quarry LP bought a new stake in Kymera Therapeutics in the 3rd quarter valued at $95,000. Thrivent Financial for Lutherans bought a new position in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $313,000. Finally, Walleye Capital LLC bought a new stake in shares of Kymera Therapeutics in the 3rd quarter valued at approximately $472,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a "market perform" rating and a $55.00 target price for the company. BTIG Research began coverage on Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Stephens reiterated an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $56.36.

Remove Ads

Kymera Therapeutics Stock Up 3.6 %

NASDAQ KYMR traded up $1.16 on Monday, hitting $33.70. The stock had a trading volume of 416,570 shares, compared to its average volume of 513,369. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -14.40 and a beta of 2.22. The company's 50-day moving average is $36.79 and its two-hundred day moving average is $42.27. Kymera Therapeutics, Inc. has a one year low of $29.07 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,788 shares of company stock worth $455,202 over the last ninety days. 15.82% of the stock is currently owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.